ATE293458T1 - Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen - Google Patents

Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Info

Publication number
ATE293458T1
ATE293458T1 AT97938475T AT97938475T ATE293458T1 AT E293458 T1 ATE293458 T1 AT E293458T1 AT 97938475 T AT97938475 T AT 97938475T AT 97938475 T AT97938475 T AT 97938475T AT E293458 T1 ATE293458 T1 AT E293458T1
Authority
AT
Austria
Prior art keywords
treatment
neuropathic pain
preparation containing
anticonvulsive agents
nmda receptor
Prior art date
Application number
AT97938475T
Other languages
English (en)
Inventor
Frank S Caruso
Fredrick L Minn
John W Lyle
Original Assignee
Algos Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Pharm Corp filed Critical Algos Pharm Corp
Application granted granted Critical
Publication of ATE293458T1 publication Critical patent/ATE293458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97938475T 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen ATE293458T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2450896P 1996-08-23 1996-08-23
PCT/US1997/014680 WO1998007447A1 (en) 1996-08-23 1997-08-21 Anticonvulsant containing composition for treating neuropathic pain

Publications (1)

Publication Number Publication Date
ATE293458T1 true ATE293458T1 (de) 2005-05-15

Family

ID=21820954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938475T ATE293458T1 (de) 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Country Status (9)

Country Link
US (2) US6187338B1 (de)
EP (1) EP0942752B1 (de)
JP (1) JP2001500121A (de)
AT (1) ATE293458T1 (de)
AU (1) AU4078897A (de)
CA (1) CA2264182A1 (de)
DE (1) DE69733081T2 (de)
ES (1) ES2241055T3 (de)
WO (1) WO1998007447A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
AU784225B2 (en) * 1997-09-08 2006-02-23 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
JP3782935B2 (ja) * 1997-09-08 2006-06-07 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法
AU2002301365B2 (en) * 1997-09-08 2005-11-24 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1094817A1 (de) 1998-07-09 2001-05-02 Warner-Lambert Company Zusammensetzungen enthaltend gaba-analoge und koffein
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US6309858B1 (en) 1998-09-29 2001-10-30 Syntex (U.S.A.) Llc T-type calcium channel variants; compositions thereof; and uses
DK1154996T3 (da) * 1999-02-18 2004-02-16 Ortho Mcneil Pharm Inc Aminoacylaroylpyrroler til behandling af neuropatisk smerte
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
DK1169060T3 (da) 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
AU5824800A (en) * 1999-06-23 2001-01-31 Warner-Lambert Company Use of fosphenytoin for the treatment of acute neuropathic pain
PL213323B1 (pl) * 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie
WO2002002521A2 (en) 2000-06-30 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. Aroyl aminoacyl pyrrole compounds and their pharmaceutical use
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
WO2002100434A1 (en) 2001-06-07 2002-12-19 The General Hospital Corporation Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
DK1423168T3 (da) 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
EP1471909A4 (de) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems
BRPI0307673A2 (pt) * 2002-02-13 2016-11-08 Beth Israel Hospital métodos de tratar doença vascular.
RU2004126093A (ru) * 2002-02-26 2005-04-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1524981B1 (de) * 2002-07-29 2009-03-11 Glaxo Group Limited Zusammensetzung mit verzögerter freisetzung enthaltend lamotrigin
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
WO2005019166A2 (en) * 2003-06-11 2005-03-03 Neuromolecular, Inc. Method of targeting a therapeutic agent
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
EP1686967A4 (de) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
EP1715843A1 (de) * 2004-01-29 2006-11-02 Neuromolecular Inc. Kombination eines nmda-rezeptor-antagonisten und eines mao-hemmers oder eines gadph-hemmers zur behandlung von erkrankungen im zusammenhang mit dem zentralen nervensystem
WO2005079773A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (de) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20060286167A1 (en) * 2005-05-02 2006-12-21 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
WO2006122035A2 (en) * 2005-05-06 2006-11-16 University Of Maryland, Baltimore Method for treating central pain syndrome or for inducing centrally generated pain in an animal model
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
JP5050851B2 (ja) * 2005-06-27 2012-10-17 小野薬品工業株式会社 疼痛治療剤
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
EP1963280B1 (de) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
EP2428207A1 (de) * 2006-12-22 2012-03-14 Allergan, Inc. Alpha-2B Adrenerger Rezeptoragonist und Serotonin-Norepinephrin-Wiederaufnahmeinhibitor-Zusammensetzungen zur Behandlung von chronischen Schmerzen
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
ES2416723T3 (es) * 2007-10-09 2013-08-02 Merck Patent Gmbh Composiciones farmacéuticas que contienen benfotiamina y gabapentina
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010036937A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
CA2994873A1 (en) * 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
HRP20220112T1 (hr) 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
WO2018106108A1 (en) 2016-12-06 2018-06-14 KEPPEL HESSELING, Jan Marius Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
MA51978A (fr) 2016-12-06 2021-01-20 Hesselink Jan Marius Keppel Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique
CA3093401A1 (en) * 2018-04-16 2019-10-24 Biogen Ma Inc. Methods of treating neuropathic pain
JPWO2020054872A1 (ja) * 2018-09-14 2021-12-02 国立大学法人富山大学 急性帯状疱疹痛の治療剤
JP2023524522A (ja) 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
JPH02502546A (ja) * 1987-12-22 1990-08-16 ファーカニー、ジョン　ダブリュ 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤
US4906638A (en) * 1987-12-22 1990-03-06 Nova Pharmaceutical Corporation Dextromethorphan potentiator for anticonvulsant composition and method
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

Also Published As

Publication number Publication date
WO1998007447A1 (en) 1998-02-26
ES2241055T3 (es) 2005-10-16
EP0942752A1 (de) 1999-09-22
EP0942752B1 (de) 2005-04-20
US6187338B1 (en) 2001-02-13
DE69733081D1 (de) 2005-05-25
US20010008889A1 (en) 2001-07-19
US6406716B2 (en) 2002-06-18
CA2264182A1 (en) 1998-02-26
AU4078897A (en) 1998-03-06
JP2001500121A (ja) 2001-01-09
DE69733081T2 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE293458T1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
ATE214277T1 (de) Schmerzlindernde arzneistoffzusammensetzung
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
PL318172A1 (en) Novel analgesic pharmaceutic preparation
ATE288444T1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
BG103552A (bg) Терапевтични средства
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
BR9508671A (pt) Método de alívio da dor e composição terapêutica
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
PL312198A1 (en) Application of procaine in obtaining a pharmaceutical preparation of analgesic activity with minimum motorial blocking effect
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
MX9707719A (es) Preparado en combinacion que contiene tramadol y un antagonista del canal de calcio.
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties